MQX-503, a novel topical nitroglycerin formulation, improves severity of symptoms associated with Raynaud's phenomenon

Jill Belch, David Fiorentino, Cluistopher Denton, Ariane Herrick, Sangeeta Sule, Virginia Steen, Naomi Rothfield, Agneta Scheja, Lee Shapiro, Joseph Shanahan, Paul Emery, Lorinda Chung, Jeffrey K. Gregory

    Research output: Contribution to journalBook/Film/Article review

    Original languageEnglish
    Pages (from-to)S622-S622
    Number of pages1
    JournalArthritis & Rheumatism
    Volume58
    Issue number9
    Publication statusPublished - Sep 2008

    Cite this

    Belch, J., Fiorentino, D., Denton, C., Herrick, A., Sule, S., Steen, V., Rothfield, N., Scheja, A., Shapiro, L., Shanahan, J., Emery, P., Chung, L., & Gregory, J. K. (2008). MQX-503, a novel topical nitroglycerin formulation, improves severity of symptoms associated with Raynaud's phenomenon. Arthritis & Rheumatism, 58(9), S622-S622.